The tissue-agnostic signature such as TMB-H and dMMR/MSI-H holds promise to guide the prescription of PD-1/PD-L1 therapy, but their predictive value is limited by the lack of pre-defined criteria for each product in a specific tumor. Here, PDCD1 is linked to neoplasm.